Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Factorial Partners LLC

Factorial Partners LLC decreased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 15.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 290,000 shares of the company’s stock after selling 55,000 shares during the period. Teva Pharmaceutical Industries comprises about 6.0% of Factorial Partners LLC’s investment portfolio, making the stock its largest holding. Factorial Partners LLC’s holdings in Teva Pharmaceutical Industries were worth $9,051,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Global Retirement Partners LLC increased its holdings in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after buying an additional 292 shares in the last quarter. Banque Cantonale Vaudoise increased its holdings in shares of Teva Pharmaceutical Industries by 6.3% during the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after buying an additional 306 shares in the last quarter. Ethic Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 1.8% during the fourth quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after buying an additional 325 shares in the last quarter. Allworth Financial LP increased its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TEVA. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. The Goldman Sachs Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, Piper Sandler reissued an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Insider Buying and Selling

In other news, CEO Richard D. Francis sold 20,025 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $634,191.75. Following the completion of the transaction, the chief executive officer owned 1,170,639 shares of the company’s stock, valued at $37,074,137.13. The trade was a 1.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the completion of the transaction, the executive vice president directly owned 172,184 shares of the company’s stock, valued at $6,131,472.24. This trade represents a 47.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 491,524 shares of company stock worth $16,789,555 over the last ninety days. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $34.51 on Tuesday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35. The firm has a market capitalization of $39.68 billion, a price-to-earnings ratio of 25.95, a price-to-earnings-growth ratio of 3.60 and a beta of 0.86. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The firm has a fifty day moving average of $32.45 and a 200-day moving average of $31.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion during the quarter. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.